LUPUS nephritis biomarkers remain a major area of interest, but few currently show enough evidence to reflect kidney histopathology and support clinical use.
Lupus Nephritis Biomarkers Show Uneven Evidence
Lupus nephritis has a variable disease course and requires ongoing monitoring, creating a clear need for reliable noninvasive biomarkers. In this review, investigators assessed the existing literature on lupus nephritis biomarkers that correlate with histopathologic findings, focusing on their potential to reflect biopsy-based disease activity and chronic damage.
The analysis included studies published between 2012 and 2024 in adults with biopsy proven lupus nephritis. Investigators examined correlations between biomarkers and key histologic measures, including the National Institutes of Health activity and chronicity indices, the International Society of Nephrology/Renal Pathology Society classes, and specific active and chronic lesions.
A total of 93 articles were included, evaluating more than 100 biomarkers. However, study quality was a major limitation. Using a standardized scoring system, a multidisciplinary expert panel found that 68% of the articles were weak or very weak. This finding suggests that although many lupus nephritis biomarkers have been proposed, most lack the methodological strength required for clinical implementation.
Which Lupus Nephritis Biomarkers Stand Out
Among the studies rated adequate or robust, five biomarkers emerged as the most promising candidates for future clinical use: transforming growth factor β1, pentraxin-3, soluble CD163, CD11b, and interleukin-16. These biomarkers showed potential to reflect specific histopathologic features and appeared to outperform traditional tests in selected settings.
Still, the review makes clear that the number of lupus nephritis biomarkers meeting this standard remains limited. Methodologic heterogeneity across studies continues to restrict interpretation and comparison. Differences in study design, biomarker selection, and outcome definitions remain key barriers to progress.
The authors support further validation of the most promising biomarkers rather than broad clinical adoption at this stage. For now, biopsy linked assessment remains central to lupus nephritis evaluation, while research continues to identify noninvasive markers that can more accurately capture histopathologic changes and improve patient monitoring.
Reference
Querin V et al. Biomarkers of Lupus Nephritis Histopathology: Where Do We Stand? Arthritis Rheumatol. 2026;78(3):548-557.
Featured Image: Chinnapong on Adobe Stock.
